Hepanib 200 MG (Sorafenib)

Basic Product Information of Hepanib (Sorafenib) 200mg

How Hepanib (Sorafenib) Works

Hepanib contains Sorafenib, an oral kinase inhibitor that decreases tumour cell proliferation by acting on multiple targets at once. Sorafenib inhibits intracellular kinases including CRAF, BRAF, and mutant BRAF, which are part of a key signalling pathway driving cancer cell growth, as well as cell-surface receptor kinases including KIT, FLT-3, RET/RET-PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta.

By blocking these targets, Hepanib interrupts both the internal signalling that drives tumour cell proliferation and the external VEGFR/PDGFR-mediated angiogenesis that tumours depend on to form new blood vessels. In pre-clinical models of hepatocellular carcinoma, renal cell carcinoma, and thyroid carcinoma, Sorafenib was shown to reduce tumour angiogenesis and increase tumour cell apoptosis (programmed cell death).

Hepanib is taken as a twice-daily oral tablet, and has been an established treatment option in liver, kidney, and thyroid cancer since its original approval for renal cell carcinoma in 2005, later extended to hepatocellular carcinoma and radioactive iodine-refractory thyroid carcinoma.

Indications for Hepanib (Sorafenib)

Hepanib (Sorafenib) is indicated for the following conditions:

Benefits of Hepanib (Sorafenib) 200mg

How to Take Hepanib (Sorafenib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Hepanib treatment. Your oncologist will monitor liver function tests, blood pressure, checked weekly during the first 6 weeks and periodically thereafter, and signs of cardiac ischaemia in patients with coronary artery disease. Monitoring also includes assessment for bleeding, skin reactions such as hand-foot skin reaction and rash, and, where indicated, ECG monitoring for QT prolongation. Report any severe abdominal pain, chest pain, unusual bleeding, severe skin reactions, severe headache, or signs of a heart attack or stroke to your doctor immediately.

Drug Interactions and Important Information

Hepanib in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer, due to a demonstrated increase in mortality in this specific combination and cancer type. Caution is advised when combining Sorafenib with other chemotherapy agents such as docetaxel or doxorubicin, as combined toxicity may be increased; your oncologist will determine whether dose adjustment of either agent is needed.

Neomycin significantly reduces Sorafenib absorption and should be used with caution. Proton pump inhibitors such as omeprazole do not require dose adjustment when used with Hepanib, despite the pH-dependent solubility of Sorafenib. Verify pregnancy status before starting treatment; women of childbearing potential should use effective contraception during treatment and for 6 months after the final dose, and men with partners of childbearing potential should use effective contraception during treatment and for 3 months after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Hepanib.

Side Effects and Precautions

Who Should Use Hepanib (Sorafenib)?

Hepanib is suitable for adult patients diagnosed with unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or locally recurrent or metastatic differentiated thyroid carcinoma that is refractory to radioactive iodine treatment. It is prescribed by medical oncologists experienced in managing multikinase inhibitor therapy and its associated cardiovascular, hepatic, and dermatologic risks. A thorough medical assessment including liver function, blood pressure, cardiac risk evaluation, and bleeding risk is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Hepanib under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Hepanib is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Nexavar by Bayer at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Hepanib (Sorafenib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Hepanib (Sorafenib) from Mediaid Pharmacy?

Hepanib represents a well-established, versatile option across three distinct cancer types. As the generic equivalent of Nexavar by Bayer, it delivers the same active ingredient, Sorafenib, with the same proven multikinase inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Hepanib gives patients worldwide access to advanced targeted cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Sorafenib option with worldwide delivery, Hepanib from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Hepanib (Sorafenib)